Finance

A recent study indicates a growing trend among Gen Z individuals to involve their parents in crucial early-career financial discussions, particularly salary negotiations. This phenomenon highlights a generational shift in workplace confidence and preparedness, prompting experts to weigh the benefits and drawbacks of such parental involvement in shaping long-term career trajectories.

The Shifting Landscape of Early Career Negotiations

In the contemporary job market, a notable percentage of Gen Z workers, specifically almost three out of every ten, are turning to their parents for assistance during their inaugural salary negotiations. This finding stems from a comprehensive Zety survey of 1,001 Gen Z employees. The survey further illustrates that young adults frequently seek their parents' guidance for various career-related tasks, including resume refinement (44%) and initial employer outreach (21%).

For those navigating salary discussions, 18% received valuable advice from their parents, while a more direct 10% had a parent engage directly with the prospective employer. This trend underscores the significant financial implications of initial salary agreements, which can profoundly influence an individual's lifetime earnings, future raises, bonuses, and retirement contributions. Estimates suggest that neglecting to negotiate an initial salary could lead to a loss of $1 million to $1.5 million over a career, as per Carnegie Mellon research. A more conservative estimate by ZipRecruiter indicates that even a $5,000 disparity in starting pay can escalate to approximately $750,000 over 45 years due to compounding effects.

Despite these high stakes, a 2025 Resume Genius survey reveals that 55% of American workers do not negotiate their initial job offers. However, for those who do, the rewards are substantial, with 78% reporting improved offers. Notably, 65% of Gen Z workers who forewent negotiation expressed regret.

Jasmine Escalera, a career expert at Zety, attributes this hesitancy to a lack of formal education in compensation, benefits, and self-advocacy. This deficiency leaves young professionals feeling uncomfortable and inexperienced in negotiation, leading them to rely on more seasoned individuals. Additionally, early-career workers often undervalue their contributions, perceiving internships, academic achievements, or volunteer work as insufficient leverage, thus feeling a greater need for the job than the employer needs them.

Career development professionals emphasize a critical distinction between supportive guidance and direct intervention. Parental review of offer letters and coaching on talking points are considered beneficial mentoring. However, direct parental engagement with hiring managers during benefit negotiations is seen as potentially detrimental. The Zety survey indicates that 67% of Gen Z workers regularly receive career advice from their parents, with 32% citing parents as the primary influence on career decisions, 35% crediting their boss, and 34% acknowledging equal influence from both.

Escalera advises that the most effective parental support empowers young adults to lead their own conversations. This includes practicing negotiation scenarios, educating them on salary range research, and helping them articulate their value based on existing experiences. Parents can also serve as role models for self-advocacy and connect their children with mentors who can offer professional guidance.

Experts caution that individuals who fail to develop self-advocacy skills early in their careers may face challenges in requesting raises, addressing workplace conflicts, or navigating difficult managerial relationships without a parental safety net. This sentiment is echoed by many Gen Zers, with over half (55%) expressing embarrassment or displeasure if a parent contacted their boss without prior consent.

This evolving dynamic highlights the need for educational institutions and employers to better equip young professionals with the necessary skills for independent career management, fostering confidence and self-reliance in the competitive job market.

This shift in Gen Z's approach to career negotiation reveals a broader societal change where parental involvement extends further into young adulthood than in previous generations. While supportive guidance is undeniably valuable, there's a fine line between empowering young professionals and inadvertently hindering their development of essential self-advocacy skills. The long-term implications for independence, career progression, and personal growth warrant careful consideration from educators, employers, and parents alike. Fostering resilience and negotiation prowess in Gen Z will be crucial for their future success and economic well-being.

This report reiterates a positive outlook on Coherus Oncology, maintaining a 'Buy' recommendation despite recent market fluctuations. The company's innovative immunotherapy pipeline is a primary driver of this optimism, with several significant clinical milestones anticipated in the near future. The focus remains on the potential of its lead drug candidates to address unmet medical needs in oncology.

A critical period for Coherus Oncology is rapidly approaching, with mid-2026 set as the timeline for crucial data releases. Investors and stakeholders are eagerly awaiting the phase 2 results for casdozokitug, particularly its efficacy in treating hepatocellular carcinoma (HCC). Concurrently, the ongoing JUPITER-02 trial for toripalimab, targeting nasopharyngeal carcinoma, is expected to provide long-term survival data that could significantly impact the drug's market position and future prospects. These readouts are considered pivotal for the company's valuation and strategic direction.

While the clinical pipeline shows considerable promise, financial sustainability remains a key consideration. Coherus Oncology currently possesses approximately $115.2 million in cash and an additional $51.8 million in marketable securities. This capital is estimated to provide operational liquidity for two to three quarters based on the current cash burn rate. Should the burn rate decrease, this runway could potentially extend to four to five quarters. However, the need for further financing is a palpable concern, especially as the company approaches these critical clinical milestones that require substantial investment.

The competitive landscape for PD-1 inhibitors and the static revenue generation from toripalimab are factors that moderate overall enthusiasm. Despite these challenges, the forthcoming early-stage clinical data are the most significant elements influencing the company's valuation trajectory. Positive results from these trials could catalyze substantial growth and validate the strategic investments made in its immunotherapy platform. Conversely, any setbacks could intensify financial pressures and necessitate more immediate capital-raising efforts.

In summary, Coherus Oncology stands at a pivotal juncture, balancing promising clinical developments with financial management challenges. The success of upcoming data readouts for casdozokitug and toripalimab will be instrumental in shaping its future trajectory and determining its long-term viability in the competitive oncology market. Careful monitoring of both clinical progress and financial health is essential for assessing the company's investment potential.